Blog Archives for category Clinical trials

medicine

FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease

FESCA is very happy to share the news, that the U.S. Food and Drug Administration (FDA) has granted   Fast Track… Continue reading »

Phase 2 clinical study for patients with diffuse cutaneous systemic sclerosis (dcSSc) or patients with pulmonary arterial hypertension (PAH)

The American company, Cumberland Pharmaceuticals, is conducting a phase 2 clinical study evaluating the safety and effectiveness of a new… Continue reading »

Press Release – Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease

Today, Boehringer Ingelheim sent out a press release, announcing that, “… the European Commission (EC) and U.S. Food and Drug Administration… Continue reading »

research2

Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (Clinical trial)

Did you know, that you can look up clinical trials on scleroderma on following sites: https://clinicaltrials.gov/ and https://www.clinicaltrialsregister.eu/ For instance you can find… Continue reading »